https://www.selleckchem.com/pr....oducts/Gefitinib.htm
EGFR-mutant lung adenocarcinoma transformation to squamous cell carcinoma appears to be a mechanism of acquired EGFR tyrosine kinase inhibitor (TKI) resistance. It is challenging for treatment, because the therapeutic strategies to adopt in these cases are still unclear. The prognosis after transformation is generally poor, and treatment is largely ineffective. This article is protected by copyright. All rights reserved.DISEASE OVERVIEW Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (